Market Overview

UPDATE: Morgan Stanley Upgrades Align Technology to Equal-Weight on Trends, Limited Competition

Related ALGN
5 Health Care Stocks Hurting From The Affordable Care Act
Align Technology Surges 5% Amid Credit Suisse Upgrade

Morgan Stanley raised its rating on Align Technology (NASDAQ: ALGN) from Underweight to Equal-weight and suspended its previous $25 price target.

Morgan Stanley said, "Our Underweight thesis anticipated pressure from consumer spending and competition. Consumer pressure has emerged and pressured growth and valuation, but FDA barriers continue to restrain potential competitors while buying time for Align to expand its low end product line and reduce price to limit potential discounts from new entrants. Our base case forecast for ~8-10% organic growth in 2013 (1% < consensus) reflects (i) stable 10% new customer adds per year; (ii) price decline moderation to -3%; and (iii) utilization growth, particularly in the orthodontist channel. We assume US discretionary spend recovers, competitors are slow to capture share if approved, and Align wins in litigation vs. ClearCorrect; visibility on each is limited."

Align Technology closed at $28.40 on Wednesday.

Latest Ratings for ALGN

DateFirmActionFromTo
Oct 2014Goldman SachsUpgradesNeutralBuy
Oct 2014Credit SuisseUpgradesNeutralOutperform
Jul 2014JefferiesMaintainsHold

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (ALGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters